Japan’s Shionogi To Buy Sciele Of U.S. For $1.4 Billion
This article was originally published in PharmAsia News
Executive Summary
Shionogi of Japan plans to pay $1.4 billion to acquire the U.S. firm Sciele Pharma in a foreign expansion move. The company becomes the latest in a string of Japanese pharmaceutical companies to buy firms abroad as Japan moves to reduce the prices of drugs for its citizens. Based partly on its best-seller drug Crestor (rosuvastatin) for lowering cholesterol, 82 percent of Shionogi's sales currently come from Japan. The purchase would expand the Japanese company's research and development stafff and provide it with its own U.S. sales staff. Shionogi suffered its slowest growth in profit in the first half of this year even though sales increased by 3 percent. (Click here for more
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.